Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

CagriSema, for example, combines semaglutide, the main pharmaceutical ingredient in the company’s approved obesity med Wegovy ... have improved the average weight loss magnitude for amycretin ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Wegovy is Novo Nordisk's flagship obesity ... Early-stage trials announced in September, showed average weight loss of 13.1% after 12 weeks. The company said at the time that the treatment was ...

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

In June 2021, Wegovy was approved for weight loss. All three drugs have become ... for obesity only was 854 as of July 2024. The average state-cost per prescription was just under $1,300.